Most Read Articles
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Elvira Manzano, 5 days ago
Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.
Elaine Soliven, 06 Jul 2020
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.
Natalia Reoutova, 07 Jul 2020

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).

FDA-approved weight loss drugs modestly improve cardiometabolic risk factors

17 Jan 2018

Weight loss medications that have received the Food and Drug Administration (FDA) approval appear to confer only modest positive benefits for cardiometabolic risk profile, according to a study.

Researchers conducted a systematic review and meta-analysis of randomized clinical trials investigating the effects of at least 1 year of treatment with FDA-approved weight loss medications (eg, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate and liraglutide) in obese adults as compared with placebo or another active agent.

Outcomes investigated were changes in blood glucose (fasting blood glucose [FBG] and haemoglobin A1c [A1c]), cholesterol profile (low-density lipoprotein and high-density lipoproteins [HDL]), blood pressure (BP; systolic/diastolic) and waist circumference (WC). Quality of evidence was evaluated using GRADE.

Pooled data from 28 trials, including 29,018 participants (median body mass index, 36.1 kg/m2), showed that weight loss medications were associated with a modest reduction in FBG (weighted mean difference [WMD], –4.0 mg/dL; 95 percent CI, –4.4 to –3.6) and in WC (WMD, –3.3 cm;–3.5 to –3.1). The drugs did not produce clinically meaningful changes in systolic/diastolic BP or cholesterol profile compared with placebo (standardized mean difference, <0.2), with the effects varying among drugs.

In particular, treatment with phentermine-topiramate resulted in a substantial reduction in WC, as well as a modest decrease in FBG, A1c and BP, with a minimal effect on cholesterol. Liraglutide use led to a substantial decrease in FBG, A1c and WC, with a minimal effect on BP and cholesterol. Naltrexone-bupropion use, on the other hand, was associated with moderate increase in HDL cholesterol with a minimal effect on FBG and WC. Finally, orlistat treatment delivered a reduction in low-density lipoprotein and HDL-cholesterol. None of these drugs produced improvements in all cardiometabolic risk factors.

Researchers called for additional studies to investigate the long-term cardiometabolic benefits of these weight loss medications. 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Elvira Manzano, 5 days ago
Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.
Elaine Soliven, 06 Jul 2020
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.
Natalia Reoutova, 07 Jul 2020

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).